Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754498 | 0.91 | LIPG (0.38) | LIPGPDE3BPDE3AGPR55CNR2 | |
| SCHEMBL754083 | 0.90 | LIPG (0.45) | LIPGGPR55CNR2HSP90AA1CNR1 | |
| SCHEMBL2777687 | 0.81 | LIPG (0.37) | LIPGPDE3BPDE3AGPR55CNR2 | |
| SCHEMBL754111 | 0.80 | LIPG (0.45) | LIPGGPR55CNR2MEN1KMT2A | |
| SCHEMBL764278 | 0.78 | NPSR1 (0.39) | LIPGPDE3BPDE3AGPR55CNR2 | |
| SCHEMBL752993 | 0.78 | LIPG (0.40) | LIPGPDE3BPDE3AGPR55CNR2 | |
| SCHEMBL754547 | 0.77 | LIPG (0.38) | LIPGPDE3BPDE3AGPR55CNR2 | |
| SCHEMBL752760 | 0.77 | NPSR1 (0.35) | LIPGGPR55CNR2MEN1KMT2A | |
| SCHEMBL765758 | 0.76 | CNR2 (0.37) | GPR55CNR2MEN1KMT2AHSP90AA1 | |
| SCHEMBL2486832 | 0.74 | ALDH1A1 (0.41) | LIPGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | LIPG 4229/4885PDE3B 2465/4885PDE3A 2706/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | LIPG 4229/4885PDE3B 2465/4885PDE3A 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.